国产非激素类创新药为湿疹治疗添新解

Core Insights - The trend of consumerization in pharmaceutical consumption is leading to increased patient involvement in treatment decisions, with safety and brand reputation becoming the primary considerations when purchasing medications [1] - The innovative non-hormonal drug, Zeli Mei Ben Wei Mo De Cream, is leading the market upgrade in the treatment of atopic dermatitis (eczema) [1] Industry Overview - Approximately 70 million eczema patients in China, with over 90% requiring topical treatments [2] - Traditional treatments have limitations such as limited efficacy, significant side effects, and a tendency for relapse after discontinuation [2] - Zeli Mei is the first globally approved aromatic hydrocarbon receptor modulator for eczema treatment in children over 2 years and adults, addressing the core issues of traditional therapies [2] Clinical Efficacy - Zeli Mei has shown a significant improvement in treatment outcomes, with nearly 60% of patients experiencing deep itch relief after 8 weeks, and over 80% efficacy in children [2] - In a Chinese Phase III clinical trial, 70% of patients remained relapse-free for 10 months after stopping treatment [2] - Clinical cases demonstrate rapid symptom relief, with 73% of pediatric patients showing significant improvement after treatment [3]